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Background: We have observed different clinical responses to botulinum toxin A (BTX-A) in patients who had
similar urodynamic parameters before the procedure. Furthermore, some bladders evaluated by cystography and
cystoscopy during the procedure had different characteristics that could influence the outcome of the treatment.
The aim of this study was to assess whether cystography and urodynamic parameters could help predict which
patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergics respond better to treatment
with injection of BTX-A.
Methods: In total, 34 patients with spinal cord injury were prospectively evaluated. All patients emptied their bladder
by clean intermittent catheterization (CIC) and had incontinence and NDO, despite using 40 mg or more of intravesical
oxybutynin and undergoing detrusor injection of BTX-A (300 IU). Pretreatment evaluation included urodynamic, and
cystography. Follow-up consisted of urodynamic and ambulatory visits four months after treatment. The cystography
parameters used were bladder shape, capacity and presence of diverticula. Urodynamic parameters used for assessment
were maximum cystometric capacity (MCC), maximum detrusor pressure (MDP), compliance and reflex volume (RV).
Results: After injection of BTX-A, 70% of the patients had success, with 4 months or more of continence. Before the
treatment, there were significant differences in most urodynamic parameters between those who responded successfully
compared to those who did not. Patients who responded successfully had greater MCC (p = 0.019), higher RV (p = 0.041),
and greater compliance (p = 0.043). There was no significant difference in the MDP (0.691). The cystography parameters
were not significantly different between these groups bladder shape (p = 0.271), capacity (p > 0.720) and presence of
diverticula (p > 0.999). Statistical analyses were performed using SPSS (version 20.0) and included Student’s t-test for
two paired samples and Fisher’s exact test, with a significance threshold of 0.05.
Conclusions: This study suggests that the cystography parameters evaluated cannot be used to help predict the
response to injection of BTX-A in the treatment of refractory NDO. However, the urodynamic parameters were
significantly different in patients who responded to the treatment, with the exception of the MDP.
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Botulinum toxin (BTX), which was described by Van
Ermengem [1] in 1897, exists as serotypes A, B, C, D, E, F
and G [2]. Currently, serotypes A and B are available for
clinical use. When injected into the muscle, BTX causes
flaccid paralysis by inhibiting acetylcholine release at the
presynaptic cholinergic junction. This effect is transient
and dose-related. In smooth muscle, it was shown by
Smith et al. [3] that BTX-A affects the release of acetyl-
choline and norepinephrine in the bladder and urethra,
respectively.
The treatment of neurogenic detrusor overactivity (NDO)
with an injection of BTX-A into the detrusor muscle
was introduced in 2000 [4]. This therapy is a minimally
invasive treatment option, and, although more invasive
than oral treatment with anticholinergic, is less invasive
than surgery [4]. Its safety and efficacy has been confirmed
in a randomized, placebo-controlled clinical trial [5]. Some
studies have evaluated the use of BTX-A injections in the
detrusor muscle of patients with spinal cord injury to
reduce NDO, increase bladder capacity, reduce incontin-
ence and improve the quality of life of these patients [5,6].
In previous studies, we have observed different clinical
responses to BTX-A in patients who had similar urody-
namic parameters before the procedure [7]. This study
was motivated by the observation that some bladders
evaluated by cystography and cystoscopy during the
procedure revealed different characteristics that could
influence the outcome of the treatment. With respect
to the morphology observed in cystography, we investigated
whether differences in diverticula, shape, and capacity could
influence the results of treatment. Similarly, we assessed
whether the urodynamic parameters evaluated before
the procedure could help predict the results of detrusor
BTX-A injection for the treatment of NDO refractory
to anticholinergics.Figure 1 The shape of the bladder (“rounded” shape, “pear-shaped”Methods
Thirty-four patients with spinal cord injury who received
injections of BTX-A between January 2012 and July 2013
participated of this prospective observational study. The
sample size was determined by G*Power software, version
3.1.7 [8] for two dependent groups (matched pairs).
Parameters used in the calculations were as follows: effect
size, 0.50; significance probability, 0.05; and power test,
0.80. Of the 34 patients, 23 were male and 11 were female.
All methods and definitions were based on the stand-
ardization of terminology of lower urinary tract function,
as described by Abrams et al. [9]. The study was approved
by the ethics committee of Sarah Hospital in Brasilia
(CAAE 24188413.3.0000.0022). Informed consent was
obtained from all patients participating in the study.
The inclusion criteria for the injection of BTX-A were
those patients who emptied their bladder by CIC and had
urinary incontinence due to hyperactivity refractory to
intravesical oxybutynin doses equal or greater than 40 mg.
An evaluation was conducted before the procedure and
included a clinical history, physical examination, ultrason-
ography of the kidneys and urinary tract, cystography and
urodynamic tests (Multichannel Urodynamics - Medtronic
Duet systems, version 8.20, Minneapolis). The following
urodynamic parameters were measured: reflex volume
(RV), maximum detrusor pressure (MDP), bladder com-
pliance, and maximum cystometric capacity (MCC). For
better assessment of compliance, only the study bladders
with a capacity ≥ 150 ml were used and compliance was
measured five minutes after the end of bladder filling to
allow for stabilization of the detrusor pressure. During
cystography, the bladder filling was stopped when the
maximum capacity had been reached, urinary leakage
started, or there was supra pubic discomfort. Outcome
was assessed in relation to the bladder shape and capacity
and the presence of diverticula. The shape of the bladderor “pine”).







Cystometric capacity (ml) 335 ± 157 246 ± 138 0.019
Detrusor overactivity (cmH2O) 68 ± 27 72 ± 26 0.691
Reflex volume (ml) 243 ± 95 193 ± 103 0.041
Compliance (ml/cmH2O) 37 ± 23 20 ± 10 0.043
*Mann–Whitney U Test for two independent samples.







Cystometric capacity (ml) 309 ± 155 492 ± 193 <0.001
Detrusor overactivity (cmH2O) 70 ± 27 41 ± 20 < 0.001
Reflex volume (ml) 228 ± 99 381 ± 229 <0.001
Compliance (ml/cmH2O) 32 ± 21 29 ± 18 =0.366
*Paired, two-sided Student’s t-test.
Álvares et al. BMC Urology 2014, 14:66 Page 3 of 5
http://www.biomedcentral.com/1471-2490/14/66was characterized as either “rounded” or “pear-shaped”
and/or “pine” (see Figure 1). The cystometric capacity was
measured in milliliters. Diverticula were characterized as
absent or present, with one group consisting of patients
with a diverticula number <10 and another group with a
diverticula number ≥ 10 (Figure 1).
All procedures were performed in a hospital under
general anesthesia. Antibiotics were administered orally,
according to a urine culture, for seven days. The procedure
performed on the fifth day of the antibiotic, all patients
tested positive for bacteria. BTX- A (Westport Allergan
Pharmaceuticals Ireland - Ireland) was diluted in sterile
saline to a final concentration of 10 units/ml. Using a
19-Fr Storz cystoscope and 5 FR needle, a total of
300 IU (30 ml) was injected into 30 sites of the detrusor
muscle, sparing the trigone region, as described in Schurch
et al. [4]. Patients were instructed to continue using the
anticholinergic medication and to gradually reduce the dose
after the procedure, if it was successful and suspend its
use if possible. The treatment was considered successful if
the patient remained continent for four months or more,
with complete absence of urinary leak, regardless of the
use of the anticholinergic medication. Clinical and urody-
namic control assessments were performed 4 months after
treatment. Statistical analyses were performed using
SPSS (version 20.0) and included Student’s t-test for two
paired samples and Fisher’s exact test with a significance
threshold of 0.05. Before each t-test, the hypothesis of
equality of variances was checked using Levene’s test.
Differences between the groups were compared with the
Mann–Whitney U test for two independent samples.
Results
Of the 34 patients, 23 were male and 11 were female.
The mean age was 31.2 ± 10.3 years (mean ± standard
deviation), with a range 19–55 years. There were 28
paraplegic and 6 tetraplegic patients and 25 traumatic
and 9 non-traumatic cases. The mean time since SCI
was 5.9 ± 4.4 years, with a maximum of 19 years and a
minimum of 1 year. The patients tolerated all of the
procedures and showed no acute complications related to
the injections. Thirty patients (88.2%) were completely
continent after the procedure. Six of these patients,
however, showed little clinical response at four months
and were considered unsuccessful. Four patients (11.8%)
remained incontinent four months after treatment, al-
though there were improvements in most urodynamic
parameters and urinary losses. Twenty-four (70%) patients
remained continent for more than 4 months and were
considered successful. Twelve patients (35.2%) had an
acontractile detrusor bladder after surgery. After four
months, the following changes in the urodynamic
parameters were observed: increased MCC (P <0.001),
increased RV (p <0.001) and decreased MDP (p <0.001).The compliance did not change significantly (p = 0.366)
(Table 1). There were significant differences in most of
the pretreatment urodynamic parameters in patients
with a successful response compared with those with an
unsuccessful response. The MCC (p = 0.019), RV (0.041)
and compliance (p = 0.043) were higher in patients with
a successful response. The MDP was not significantly
different between groups (p = 0.691) (Table 2).
Regarding cystography, before the procedure, 24 patients
(70%) had no diverticula, eight patients had between 1 and
10 diverticula and 2 patients had more than 10 diverticula.
By Fisher’s exact test, there was no association between the
response and the presence of diverticula (p > 0.999), bladder
shape (p <0.271) or bladder capacity (p = 0.720) (Table 3).
After 4 months of follow-up, twenty patients (58.8%)
had reduced the dose of anticholinergics, five (14.7%) had
discontinued their use and nine (26.5%) had not changed
the dose (Table 4). Among the 24 patients with successful
results, only 5 had discontinued the use of anticholiner-
gics. However, 16 of these patients were able to decrease
the dose of the anticholinergic drugs after the procedure
(Table 5).
Discussion
BTX-A injections into the detrusor muscle provide a
clinically significant improvement in patients with NDO
refractory to anticholinergics and are very well tolerated
(5;6). In this study, continence was observed over a period
of more than 4 months in 70% of the patients undergoing
treatment with BTX-A. In studies with similar populations
of patients, the percentage of patients with continence
after injection of the toxin ranged from 42 to 87% [10].
Karsenty et al. reported that anticholinergic agents may be
discontinued in 28% to 58% of patients after treatment
Table 5 Anticholinergic use after botulinum toxin
injection (success)
Use of anticholinergics N° patients




Table 3 Results and cystography parameters
Success Unsuccess p-value*
Capacity (ml) 351,0 ± 259,3 ml 315,8 ± 212 ml P = 0,720
Forma “Rounded”
(n = 22)
17 (77%) 5 (23%) P = 0,271
“pear-shaped”/
“pine” (n = 12)
7 (58%) 5 (42%)
Diverticula Absent (n = 24) 17 (71%) 7 (29%) p > 0,999
Present (n = 10) 7 (70%) 3 (30%)
*Mann–Whitney U Test for two independent samples.
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the remaining patients [10]. In this study, after 4 months
of follow-up, twenty patients (58.8%) had reduced the dose
of anticholinergics, five (14.7%) discontinued the use and
nine (26.5%) did not change the dose of medication
(Table 4). Among the 24 patients with successful results,
only 5 had discontinued the use of anticholinergics.
However, 16 patients were able to decrease the dose of
anticholinergic drugs after the procedure (Table 5). We
note that some of these patients did not reduce the
dose because they were afraid that the urinary losses
would return after being continent. According to previous
studies, some factors that may be related to the efficacy
of BTX-A injections into the detrusor muscle include,
for example, whether the doses of anticholinergics used
before the procedure were considered high (refractory
bladder) [7], what the optimal dose of BTX-A is [11,12],
the formulations used [13,14] and the injection technique
[11]. These factors may explain some of the differences
observed in the results across different studies. The results
obtained in this study were similar to earlier studies.
Among patients presenting with NDO that is refractory
to anticholinergic agents, there was a percentage with
unsuccessful results.
Although it has been reported that alterations can
occur in the detrusor muscle of the NDO [15,16], it was
postulated that the morphology of the bladder (shape
and presence of diverticula) could be a result of these
alterations, and could, in turn, influence the response to
BTX-A injections. These changes in bladder shape are
most likely the result of smooth muscle hypertrophy and
changes in the connective tissue matrix that do not respond
to conservative treatment. However, the present study did
not demonstrate that the cystography parameters couldTable 4 Anticholinergic use after botulinum toxin
injection (Total)
Use of anticholinergics N° patients
Not decreased 9 (26,5%)
Decreased 20 (58,8%)
Suspended 5 (14,7%)
Total 34 (100%)predict which cases would be more likely to have a better
response to BTX-A injections.
Regarding urodynamic parameters, we observed in this
study that the bladders that had better compliance, greater
capacity and increased reflex volume before treatment
showed a better response to treatment. Furthermore, there
was no significant change in compliance after surgery
(p = 0.366), suggesting that compliance is related to alter-
ations in the bladder wall, is unresponsive to drug therapy,
and is, therefore, directly related to the treatment response.
This is in contrast to a study conducted by Klaphajone J
[17], in which a small number of patients did not show this
relationship.
Conclusion
This study suggests that the cystography parameters
evaluated cannot be used to predict the response to
BTX-A injection for the treatment of refractory NDO. It
was observed in the urodynamic parameters, that patients
whose bladders had higher cystometric capacity, greater
reflex volume and greater compliance showed better
results after treatment. The bladder compliance showed
no significant improvement after the procedure, which
is an important factor to be noted. A larger study with
a multivariate analysis would be appropriate to clarify
the results of this work.
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